Condition

Multiple Myeloma in Relapse clinical trials and research

• 23Clinical trials
• 8Countries

Newest Multiple Myeloma in Relapse clinical trials

All recruiting trials (23)

• In Vivo BCMA-CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

  This study tests VV169, a one-time in vivo CAR-T treatment, in adults with multiple myeloma that has come back or not responded to standard therapy.

  Recruiting Phase 1 Vyriad, Inc. · Rochester, Minnesota · NCT07802717

• Inobrodib with Pomalidomide and Dexamethasone vs Standard Therapy for Relapsed or Refractory Myeloma

  This study tests whether inobrodib with pomalidomide and dexamethasone helps people with relapsed or refractory multiple myeloma more than the standard available therapy.

  Recruiting Phase 3 CellCentric Ltd. · Miami, Florida · NCT07772024

• CAR-T therapy for relapsed or refractory multiple myeloma

  This study tests a CAR-T therapy in people with multiple myeloma whose disease has come back or not responded to treatment.

  Recruiting at 2 sites Phase 2 National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Rawalpindi, Punjab Province and 1 other locations · NCT07689058

• Elranatamab given as outpatient in relapsed or refractory multiple myeloma

  This study tests a bispecific antibody called elranatamab, given in an outpatient setting to adults with relapsed or refractory multiple myeloma who have had prior therapies.

  Recruiting at 6 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 5 other locations · NCT07637578

• Liposomal Curcumin in Multiple Myeloma: safety and dose finding

  This trial tests a novel liposomal curcumin infusion to see if it is safe and what highest tolerable dose is for adults whose multiple myeloma has returned or not responded to treatment.

  Recruiting Phase 1 University Health Network, Toronto · Toronto, Ontario · NCT07456605

• Off-the-shelf BCMA CAR‑T for relapsed or refractory multiple myeloma

  This trial will try a universal (allogeneic) BCMA-directed CAR‑T cell treatment for people with relapsed or refractory multiple myeloma to see if it is safe and can reduce disease.

  Recruiting Bioray Laboratories · Shanghai · NCT07248176

• NT-I7 added to BCMA CAR-T therapy for relapsed or refractory multiple myeloma

  This trial tests whether giving NT-I7 after BCMA CAR-T therapy helps boost T-cell expansion and possibly improve responses in people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07200089

• Inobrodib with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma

  This test tries to see if adding inobrodib to pomalidomide and dexamethasone helps people whose multiple myeloma has returned or stopped responding after standard treatments.

  Recruiting at 31 sites Phase 2 CellCentric Ltd. · Phoenix, Arizona and 30 other locations · NCT07096778

• KLN-1010 gene therapy for relapsed or refractory multiple myeloma

  This Phase 1 trial will try KLN-1010, an in vivo CAR‑T gene therapy, to see if it is safe and can be given at a tolerable dose for people with relapsed or refractory multiple myeloma who have had at least three prior therapies.

  Recruiting at 11 sites Phase 1 Kelonia Therapeutics, Inc. · Duarte, California and 10 other locations · NCT07075185

• Sequential CAR-T therapy targeting BCMA and GPRC5D for relapsed or refractory multiple myeloma

  This will try sequential CAR-T cell therapy against BCMA and GPRC5D in people with relapsed or refractory multiple myeloma to see if it is safe and helps control the disease.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07032129

• Cost-effectiveness analysis of outpatient bispecific antibody treatment for multiple myeloma.

  This study tests if treating patients with relapsed or refractory multiple myeloma using bispecific antibodies in an outpatient setting is more effective and cost-friendly than traditional hospital care.

  Recruiting University Hospital, Toulouse · Toulouse · NCT06846905

• Talquetamab treatment for elderly patients with early relapse multiple myeloma

  This study is testing if a new treatment called Talquetamab can help older patients with early relapse multiple myeloma who can't tolerate stronger therapies feel better and have a safer option.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT06827860

• Selinexor plus a commercial bispecific antibody for relapsed or refractory multiple myeloma

  This study will test whether adding selinexor to a commercial bispecific antibody helps adults with relapsed or refractory multiple myeloma reach deeper remissions and is safe.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT06822972

• Early palliative care for patients with multiple myeloma and aggressive lymphoma

  This study is testing if early palliative care can improve the quality of life and comfort for people with multiple myeloma and aggressive lymphoma while they receive their usual cancer treatment.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT06485076

• Combination treatment for relapsed or refractory multiple myeloma

  This study is testing a new combination of lower-dose Selinexor, Ruxolitinib, and methylprednisolone to see if it can help people with relapsed or refractory multiple myeloma who have few treatment options left.

  Recruiting Phase 1 Oncotherapeutics · West Hollywood, California · NCT06225310

• Using All-trans Retinoic Acid with KPD for treating relapsed multiple myeloma

  This study is testing if a new combination of All-trans Retinoic Acid and a specific treatment can help people with relapsed multiple myeloma who haven't had success with other therapies.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06158412

• Combining venetoclax with isatuximab and dexamethasone for treating relapsed/refractory multiple myeloma

  This study is testing a new combination of medications to see if it can help people with relapsed or stubborn multiple myeloma who have a specific genetic marker feel better and respond to treatment.

  Recruiting at 2 sites Phase 2 Oncotherapeutics · West Hollywood, California and 1 other locations · NCT06115135

• Combining belantamab mafodotin and venetoclax for treating relapsed multiple myeloma

  This study is testing a new combination of two drugs, belantamab mafodotin and venetoclax, to see if it helps adults with relapsed multiple myeloma that has a specific genetic change.

  Recruiting at 5 sites Phase 1/2 Universitätsklinikum Hamburg-Eppendorf · Hamburg, Ham and 4 other locations · NCT05853965

• Testing a new CAR T-cell therapy for patients with advanced B-cell cancers

  This study is testing a new CAR T-cell therapy to see if it can help adults with hard-to-treat B-cell cancers feel better and improve their health.

  Recruiting Phase 1 Technische Universität Dresden · Dresden · NCT05836896

• BCMA-targeted CAR-T cell therapy for relapsed multiple myeloma

  This study is testing a new CAR-T cell therapy that targets a specific protein in people with relapsed multiple myeloma to see if it can help them when other treatments haven't worked.

  Recruiting Phase 1/2 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT04776330

• APRIL CAR-T cell therapy for relapsed multiple myeloma patients

  This study is testing a new CAR-T cell therapy for patients with relapsed multiple myeloma to see if it is safe and effective for those who haven't responded well to other treatments.

  Recruiting Early Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT04657861

• BCMA-targeted CAR-T cell therapy for multiple myeloma

  This study is testing a new CAR-T cell therapy that targets a specific protein in multiple myeloma to see if it can help patients whose cancer has come back or hasn't responded to other treatments.

  Recruiting Phase 1/2 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT04271644

• Dual-target BCMA–CD19 CAR T-cell therapy for relapsed or refractory multiple myeloma and plasmacytoid lymphoma

  This treatment will try a dual-target CAR T-cell therapy that attacks BCMA and CD19 in people with relapsed or refractory multiple myeloma or plasmacytoid lymphoma who have exhausted standard options.

  Recruiting at 2 sites Phase 1 iCell Gene Therapeutics · Shenzhen, Guangdong and 1 other locations · NCT04162353

Related topics

Quick answers

How many Multiple Myeloma in Relapse clinical trials are recruiting right now?

23, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 8 countries. The most sites are in United States (10 trials), China (7 trials), Canada (2 trials), Germany (2 trials), Pakistan (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1: 7, Phase 1/2: 4, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →